The role of cardiac biomarkers in cardiovascular disease risk assessment

Purpose of review A range of cardiovascular biomarkers have come into the routine clinical use for the diagnosis and assessment of patients with symptomatic coronary disease. The review will consider the current evidence base for the role of measurement of a number of these biomarkers in asymptomatic patients. Recent findings Measurement of the cardiac troponins, cardiac troponin T and cardiac troponin I, using sensitive methods, defines a true reference population, and has demonstrated risk of cardiovascular events with small elevations above the reference interval and a gradient of risk across the reference range even in normal healthy individuals. Similar results can be seen for the measurement of the ventricular stress marker B-type natriuretic peptide. In an asymptomatic population, there is occult cardiovascular disease which can be detected by cardiovascular biomarker measurement. Novel markers of myocardial inflammation and fibrosis, such as growth differentiation factor 15, are also powerful predictors of mortality. Measurement of these cardiovascular biomarkers provides additional risk prediction when added to risk prediction models based on the conventional risk factors. Summary The measurement of cardiovascular biomarkers has the potential to provide additional risk stratification beyond conventional risk factors. The challenge is to translate biomarker measurements to treatment strategies which will reduce long-term cardiovascular risk.

[1]  S. Moebus,et al.  Predicting risk of coronary events and all-cause mortality: role of B-type natriuretic peptide above traditional risk factors and coronary artery calcium scoring in the general population: the Heinz Nixdorf Recall Study , 2014, European journal of preventive cardiology.

[2]  V. Salomaa,et al.  High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. , 2014, European heart journal.

[3]  L. Lind,et al.  GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men , 2013, PloS one.

[4]  D. Levy,et al.  Association of Novel Biomarkers of Cardiovascular Stress With Left Ventricular Hypertrophy and Dysfunction: Implications for Screening , 2013, Journal of the American Heart Association.

[5]  A. Jaffe,et al.  Effect of population selection on 99th percentile values for a high sensitivity cardiac troponin I and T assays. , 2013, Clinical biochemistry.

[6]  L. Lind,et al.  Associations of mid-regional pro-adrenomedullin levels to cardiovascular and metabolic abnormalities, and mortality in an elderly population from the community. , 2013, International journal of cardiology.

[7]  L. Lind,et al.  Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community-dwelling elderly individuals. , 2013, Clinical chemistry.

[8]  A. Jaffe,et al.  Defining high-sensitivity cardiac troponin concentrations in the community. , 2013, Clinical chemistry.

[9]  R. Schnabel,et al.  Association of MR-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular disease. , 2013, Atherosclerosis.

[10]  C. Ayers,et al.  Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: the Dallas Heart Study. , 2013, Clinical chemistry.

[11]  S. Silber,et al.  Prognostic value of NT-pro-BNP and hs-CRP for risk stratification in primary care: results from the population-based DETECT study , 2013, Clinical Research in Cardiology.

[12]  E. Nagel,et al.  Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease. , 2012, International journal of cardiology.

[13]  D. Levy,et al.  Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. , 2012, Journal of the American College of Cardiology.

[14]  D. Levy,et al.  Prognostic Utility of Novel Biomarkers of Cardiovascular Stress: The Framingham Heart Study , 2012, Circulation.

[15]  Gary S Collins,et al.  Interpreting diagnostic accuracy studies for patient care , 2012, BMJ : British Medical Journal.

[16]  R. Luepker,et al.  Increased cardiac troponin I as measured by a high-sensitivity assay is associated with high odds of cardiovascular death: the Minnesota Heart Survey. , 2012, Clinical chemistry.

[17]  L. Lind,et al.  Relations of growth-differentiation factor-15 to biomarkers reflecting vascular pathologies in a population-based sample of elderly subjects , 2012, Scandinavian journal of clinical and laboratory investigation.

[18]  A. Kastrati,et al.  High-sensitivity troponin T level and angiographic severity of coronary artery disease. , 2011, The American journal of cardiology.

[19]  Eric Boerwinkle,et al.  Cardiac Troponin T Measured by a Highly Sensitive Assay Predicts Coronary Heart Disease, Heart Failure, and Mortality in the Atherosclerosis Risk in Communities Study , 2011, Circulation.

[20]  A. Khera,et al.  Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. , 2010, JAMA.

[21]  M. Zhan,et al.  Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. , 2010, JAMA.

[22]  H. Kauczor,et al.  Determinants of troponin release in patients with stable coronary artery disease: insights from CT angiography characteristics of atherosclerotic plaque , 2010, Heart.

[23]  P. Collinson,et al.  Assay imprecision and 99th-percentile reference value of a high-sensitivity cardiac troponin I assay. , 2009, Clinical chemistry.

[24]  J. Struck,et al.  Copeptin: clinical use of a new biomarker , 2008, Trends in Endocrinology & Metabolism.

[25]  Richard T. Lee,et al.  IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. , 2007, The Journal of clinical investigation.

[26]  N. Cook.  Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction , 2007, Circulation.

[27]  D. Levy,et al.  Multiple biomarkers for the prediction of first major cardiovascular events and death. , 2006, The New England journal of medicine.

[28]  J. Ware.  The limitations of risk factors as prognostic tools. , 2006, The New England journal of medicine.

[29]  H. Drexler,et al.  The Transforming Growth Factor-&bgr; Superfamily Member Growth-Differentiation Factor-15 Protects the Heart From Ischemia/Reperfusion Injury , 2006 .

[30]  L. Køber,et al.  N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. , 2005, The New England journal of medicine.

[31]  Daniel Levy,et al.  Plasma natriuretic peptide levels and the risk of cardiovascular events and death. , 2004, The New England journal of medicine.

[32]  M. Sabatine,et al.  The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. , 2001, The New England journal of medicine.

[33]  Fred S Apple,et al.  Analytical characteristics of high-sensitivity cardiac troponin assays. , 2012, Clinical chemistry.

[34]  P. Collinson,et al.  Influence of population selection on the 99th percentile reference value for cardiac troponin assays. , 2012, Clinical chemistry.

[35]  A. Khera,et al.  Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multiethnic population: observations from the Dallas Heart Study. , 2012, Clinical chemistry.

[36]  Maarten L. Simoons,et al.  The third universal definition of myocardial infarction , 2013 .

[37]  H. Drexler,et al.  The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. , 2006, Circulation research.

[38]  B. Yanagawa,et al.  Adrenomedullin: molecular mechanisms and its role in cardiac disease , 2005, Amino Acids.